SCS Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

SCS Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.94M	Buy	12,260 +3	+0%	+$406	0.02%	217
2026 Q1	$1.57M	Buy	12,257 +187	+2%	+$23.3K	0.02%	224
2025 Q4	$1.47M	Sell	12,070 -9,562	-44%	-$1.1M	0.02%	242
2025 Q3	$2.17M	Buy	21,632 +4	+0%	+$360	0.02%	209
2025 Q2	$1.79M	Sell	21,628 -999	-4%	-$79.7K	0.02%	232
2025 Q1	$1.84M	Buy	+22,627	New	+$2.02M	0.02%	210

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SCS Capital Management's XBI Position: Q2 2026 in Review

SCS Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 0.02% in Q2 2026, buying an estimated $406 and bringing the position to 12,260 shares worth $1.94M. The position accounts for 0.02% of the portfolio, ranked #217.

SCS Capital Management first reported a position in XBI in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.17M in Q3 2025. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

SCS Capital Management held 12,260 shares of State Street SPDR S&P Biotech ETF worth $1.94M as of Q2 2026.
SCS Capital Management bought 3 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $406.
State Street SPDR S&P Biotech ETF made up 0.02% of SCS Capital Management's portfolio in Q2 2026, its #217 holding.
SCS Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2025 and has held it in 6 quarters since.
SCS Capital Management's State Street SPDR S&P Biotech ETF position peaked at $2.17M in Q3 2025.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on SCS Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.